


PTO-1449 REPRODUCED



SUPPLEMENTAL INFORMATION DISCLOSURE
CITATION
IN AN APPLICATION
November 16, 2004
(Use several sheets if necessary)

ATTORNEY DOCKET NO.
2629.1003-008APPLICATION NO.
10/820,478FIRST NAMED INVENTOR
Sudhir V. ShahFILING DATE
April 8, 2004EXAMINER
Not AssignedCONFIRMATION NO.
8698GROUP
1654

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
<i>M</i>	AK	US 2003/0064929 A1	04/03/2003	Duranton <i>et al.</i>

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
<i>ar</i>	AL2	WO 90/04584	05/03/1990	BIOREX KUTATO FEJLESZTO KFT.	

EXAMINER

DATE CONSIDERED

02/18/2005

PTO-1449 REPRODUCED

SECOND SUPPLEMENTAL INFORMATION
DISCLOSURE CITATION IN AN APPLICATION
August 31, 2004
(Use several sheets if necessary)

O I P E
SEP 02 2004
SEARCHED
INDEXED
MAILED
TRADEMARK OFFICE

ATTORNEY DOCKET NO.
2629.1003-008APPLICATION NO.
10/820,478FIRST NAMED INVENTOR
Sudhir V. ShahFILING DATE
April 8, 2004EXAMINER
Not AssignedCONFIRMATION NO.
8698GROUP
1654

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
W	AE	4,684,482	08-04-1987	Green
M	AF	5,047,329	09-10-1991	Suzuki
AG		6,206,849 B1	03-27-2001	Martin et al.
AH		6,383,817 B2	05-07-2002	Schwartz
AJ		6,589,966 B1	07-08-2003	Torti et al.
AJ		6,706,287 B2	03-16-2004	Ranganathan et al.

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
W	AP	WO 00/54784	09-21-2000	Aripkohodzhaeva	X
W	AQ	JP 05000949 A	01-08-1993	Santen Pharmaceuticals Co., Ltd Dai Ichi Seiyaku Co., Ltd.	X (Abstract)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

a	AWS	Fernández-Real, J.M., et al., "Cross-Talk Between Iron Metabolism and Diabetes," <i>Diabetes</i> , 51:2348-2354, 2002
a	AXS	Nitengberg, A., et al., "Coronary Microvascular Adaptation to Myocardial Metabolic Demand Can Be Restored by Inhibition of Iron-Catalyzed Formation of Oxygen Free Radicals in Type 2 Diabetic Patients," <i>Diabetes</i> , 51:813-818, 2002

EXAMINER

DATE CONSIDERED

08/18/2005

<p>PTO-1449 REPRODUCED</p> <p>SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION</p> <p>April 8, 2004</p> <p>(Use several sheets if necessary)</p>	<p>ATTORNEY DOCKET NO. 2629.1003-008</p> <p>FIRST NAMED INVENTOR Sudhir V. Shah</p>
---	---

FOREIGN PATENT DOCUMENTS

EXAMINER <i>John M. Morris</i>	DATE CONSIDERED : 02/15/2005
-----------------------------------	---------------------------------

@PFDdesktop\ODMA\MHODMA\HBSR05;iManage;465568;1

<p>PTO-1449 REPRODUCED</p> <p>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</p> <p>April 8, 2004</p> <p>(Use several sheets if necessary)</p>	<p>ATTORNEY DOCKET NO. 2629.1003-008</p> <hr/> <p>FIRST NAMED INVENTOR Sudhir V. Shah</p>
--	---

U.S. PATENT DOCUMENTS				
EXAM- INER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
<i>m</i>	AA	5,047,421	09-10-91	Green
<i>a</i>	AB	5,721,209	02-24-98	Horwitz <i>et al.</i>
<i>c</i>	AC	5,811,127	09-22-98	Milstein <i>et al.</i>
<i>v</i>	AD	5,091,180	02-25-92	Walker <i>et al.</i>

FOREIGN PATENT DOCUMENTS

EXAMINER	Dale M.	DATE CONSIDERED	01/23/2005
----------	---------	-----------------	------------


PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION		ATTORNEY DOCKET NO. 2629.1003-008
April 8, 2004 (Use several sheets if necessary)		FIRST NAMED INVENTOR Sudhir V. Shah

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
✓	AR	Sumboonnanonda, A., et al., "Renal tubular function in β-thalassemia", <i>Pediatr Nephrol</i> , 12:280-283.
✓	AS	Ong-ajyooth, L., et al., "Renal Function in Adult Beta-Thalassemia/Hb E Disease", <i>Nephron</i> , 78:156-161 (1998).
✓	AT	Guasch, A., et al., "Evidence that Microdeletions in the α Globin Gene Protect Against the Development of Sickle Cell Glomerulopathy in Humans", <i>J Am Soc Nephrol</i> , 10:1014-1019 (1999).
✓	AU	Loebstein, R., et al., "Diabetic Nephropathy in Hypertransfused Patients with β-Thalassemia", <i>Diabetes Care</i> , 21(8):1306-1309 (1998).
✓	AV	Ongajyooth, L., et al., "Glomerulonephritis in β-thalassemia Hb-E Disease: Clinical Manifestations, Histopathologic Studies and Outcome", <i>J Med Assoc Thai</i> , 78(3):119-126 (1995).
✓	AW	Aoki, R.Y., et al., "Microalbuminuria in Sickle Cell Disease", <i>Brazilian J Med Biol Res</i> , 23:1103-1106 (1990).
✓	AX	Katopodis, K.P., et al., "Renal Abnormalities in Patients with Sickle Cell-Beta Thalassemia", <i>Journal of Nephrology</i> , 10(3):163-167 (1997).
✓	AY	Pham, P.-T.T., et al., "Renal abnormalities in sickle cell disease", <i>Kidney International</i> , 57:1-8 (2000).
✓	AZ	Kontogiorges, G.J., et al., "Simple Synthesis of the Potent Iron Chelators 1-Alkyl-3-hydroxy-2-methylpyrid-4-ones", <i>Inorganica Chimica Acta</i> , 136:L11-L12 (1987).
✓	AR2	Falk, R.J., et al., "Prevalence and Pathologic Features of Sickle Cell Nephropathy and Response to Inhibition of Angiotensin-Converting Enzyme", <i>The New England Journal of Medicine</i> , 326(14):910-915 (1992).
✓	AS2	Guasch, A., et al., "Sickle cell anemia causes a distinct pattern of glomerular dysfunction", <i>Kidney International</i> , 51:826-833 (1997).
✓	AT2	Cianciulli, P., et al., "Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy", <i>Kidney International</i> , 46:467-470 (1994).
✓	AU2	Ueda, N., et al., "Role of 'catalytic' iron in an animal model of minimal change nephrotic syndrome", <i>Kidney International</i> , 49:370-373 (1996).

EXAMINER <i>Juliette</i>	DATE CONSIDERED <i>08/12/2005</i>
--------------------------	-----------------------------------


PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION	ATTORNEY DOCKET NO. 2629.1003-008
April 8, 2004 (Use several sheets if necessary)	FIRST NAMED INVENTOR Sudhir V. Shah

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
<i>m</i>	AV2	Savill, J., et al., "Mechanisms of glomerular injury". In "Oxford Textbook of Clinical Nephrology," 2 nd ed., pages 404-439, eds., Davidson, A.M., et al., Oxford Univ. Press (1998).
<i>n</i>	AW2	Ueda, N., et al., "In Vivo Evidence for a Role of Reactive Oxygen Metabolites in Glomerular Disease", <i>Kidney: A Current Survey of World Literature</i> , 6:143-146 (1997).
<i>n</i>	AX2	Boyce, N.W., et al., "Hydroxyl radical mediation of immune renal injury by desferrioxamine", <i>Kidney International</i> , 30:813-817 (1986).
<i>n</i>	AY2	Baliga, R., et al., "Kidney Iron Status in Passive Heymann Nephritis and the Effect of an Iron-Deficient Diet", <i>J Am Soc Nephrol</i> , 7(8):1183-1188 (1996).
<i>k</i>	AZ2	Shah, S.V., "Evidence suggesting a role for hydroxyl radical in passive Heymann nephritis in rats", <i>The American Physiological Society</i> , F337-F344(1988).
<i>m</i>	AR3	Thakur, V., et al., "Evidence suggesting a role for hydroxyl radical in puromycin aminonucleoside-induced proteinuria", <i>Kidney International</i> , 34:494-499 (1988).
<i>n</i>	AS3	Nankivell, B.J., et al., "The Role of Tubular Iron Accumulation in the Remnant Kidney", <i>J Am Soc Nephrol</i> , 4(8):1598-1607 (1994).
<i>n</i>	AT3	Alfrey, A.C., et al., "Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis", <i>Kidney International</i> , 36:753-759 (1989).
<i>n</i>	AU3	El Nahas, A.M., "Mechanisms of experimental and clinical renal scarring" In: "Oxford Textbook of Clinical Nephrology", 2 nd ed., pages 1749-1788, eds., Davidson, A.M., et al., Oxford Univ. Press (1998).
<i>n</i>	AV3	Howard R.L., et al., "Urinary albumin, transferrin and iron excretion in diabetic patients", <i>International Society of Nephrology</i> , 40:923-926 (1991).
<i>c</i>	AW3	Olivieri, N.F., et al., "Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major", <i>The New England Journal of Medicine</i> , 918-922 (1995).
<i>n</i>	AX3	Alfrey A.C., "Toxicity of tubule fluid iron in the nephrotic syndrome", <i>American Journal of Physiology</i> , 263(4):F637-F641 (1992).

EXAMINER 	DATE CONSIDERED 02/28/2005
---	-------------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION		ATTORNEY DOCKET NO. 2629.1003-008
April 8, 2004 (Use several sheets if necessary)		FIRST NAMED INVENTOR Sudhir V. Shah

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
dr	AY3	Wu, Z-L, et al., "Iron Loading Enhances Susceptibility to Renal Ischemia in Rats," <i>Renal Failure</i> , 16(4): 471-480 (1994).
✓	AZ3	Baliga, R., et al., "In Vitro and In Vivo Evidence Suggesting a Role for Iron in Cistaplin-induced Nephrotoxicity," <i>Kidney International</i> , 53(2): 394-401 (February 1998).
✓	AR4	Harris, D., et al., "Mitochondrial Function in Rat Renal Cortex in Response to Proteinuria and Iron," <i>Clinical and Experimental Pharmacology and Physiology</i> 24:916-922 (December 1997).
✓	AS4	Walker, P.D., et al., "Evidence Suggesting a Role for Hydroxyl Radical in Gentamicin-Induced Acute Renal Failure in Rats," <i>J Clin Invest</i> 81:334-341 (1988).
✓	AT4	Shah, S.V., et al., "Evidence Suggesting a Role for Hydroxyl Radical in Glycerol-Induced Acute Renal Failure," <i>Am J Physiol</i> 255, (Renal Fluid Electrolyte Physiol. 24):F438-F443 (1988).
✓	AU4	Baliga, R., et al., "Increase in Bleomycin-Detectable Iron in Ischaemia/Reperfusion Injury to Rat Kidneys," <i>Biochem J</i> 291(3):901-905 (1993).
✓	AV4	Kontogiorgese, G.J., et al., "Studies of Aluminium Mobilization in Renal Dialysis Patients Using the Oral Chelator 1,2-Dimethyl-3-hydroxypyrid-4-one," <i>Arzneim-Forsh/Drug Res.</i> 44(1):522-526 (1994).
✓	AW4	Baliga, R., et al., "Oxidant Mechanisms in Toxic Acute Renal Failure," <i>Drug Metabolism Reviews</i> 31(4):971-991 (1999).
✓	AX4	Walker, P.D., et al., "Gentamicin Enhanced Production of Hydrogen Peroxide by Renal Cortical Mitochondria," <i>Am J Physiol</i> 253:C495-C499 (1987).
✓	AY4	Walker, P.D., et al., "Hydrogen Peroxide Cytotoxicity in LLC-PK ₁ Cells: A Role for Iron," <i>Kidney Int</i> 40:891-898 (1991).
✓	AZ4	Abul-Ezz, S.R., et al., "Role of Glutathione in an Animal Model of Myoglobinuric Acute Renal Failure," <i>Proc Natl Acad Sci</i> 88:9833-9837 (1991).
✓	ARS	Ueda, N., et al., "Gentamicin-Induced Mobilization of Iron from Renal Cortical Mitochondria," <i>Am J Physiol</i> 265(3 Pt. 2):F435-F439 (1993).
✓	ASS	Baliga, R., et al., "Evidence for Cytochrome P-450 as a Source of Catalytic Iron in Myoglobinuric Acute Renal Failure," <i>Kidney Int</i> 49:362-369 (1996).

EXAMINER 	DATE CONSIDERED 04/13/2005
---	-------------------------------

<p>PTO-1449 REPRODUCED</p> <p>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</p> <p>April 8, 2004</p> <p>(Use several sheets if necessary)</p>	<p>ATTORNEY DOCKET NO. 2629.1003-008</p> <hr/> <p>FIRST NAMED INVENTOR Sudhir V. Shah</p>
--	---

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER 	DATE CONSIDERED 03/09/2005
---	-------------------------------

@PFDdesktop\ODMA\MHODMA\HBSR05\Manage\465305.1